相关实验视频

Updated: May 25, 2025

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Published on: February 18, 2020

在冠状动脉疾病中,扩大药物涂层气球的适用范围

Antonio Greco¹, Giacinto Di Leo¹, Marco Spagnolo¹

¹Division of Cardiology, A.O.U. Policlinico "G. Rodolico - San Marco", University of Catania, Catania, Italy.

Expert review of medical devices

|February 27, 2025

概括

药物涂层气球 (DCBs) 为穿皮冠状动脉干预 (PCI) 的药物排泄支架 (DES) 提供了一个有希望的替代方案,特别是在特殊情况下,如小血管和支架静止 (ISR). 进一步的研究正在进行中,以充分确定它们在各种冠状动脉病变治疗中的有效性和安全性.

科学领域:

心血管医学心血管医学
干预心脏病学干预心脏病学
医疗器械中的生物材料

背景情况:

通过皮肤进行冠状动脉干预 (PCI) 使用药物释放支架 (DES) 面临诸如支架血栓形成和支架静止 (ISR) 等挑战.
药物涂层气球 (DCB) 提供了一个无设备的PCI方法,与"不留任何东西"原则保持一致,在DES不合适时提供了替代方案.

研究的目的:

提供可用的药物涂层气球 (DCB) 的全面概述.
总结目前支持DCB在各种冠状动脉损伤情景中的使用证据.
为了在不同的临床环境中比较DCB与传统DES的疗效.

主要方法:

在PubMed,Web of Science和Cochrane数据库中进行了全面的文献搜索,截至2024年11月.
审查的重点是总结DCB在静脉静脉复缩 (ISR),小血管疾病,新型大血管疾病和分叉病的应用证据.
分析考虑了试验群体的异质性,样本大小,随访持续时间,解剖模式和使用的设备.

主要成果:

药物涂层气球 (DCB) 已被批准用于小血管疾病和精选的静脉静脉复缩 (ISR) 病变.
药物排泄支架 (DES) 可能更适合用于DES-ISR,大血管中的新生病变和分叉主分支治疗.
目前对DCB的试验呈现异质性,并且通常对临床终点的统计能力有限.

结论:

药物涂层气球 (DCB) 是特定冠状动脉干预的宝贵选择,特别是当金属支架植入不良时.
虽然DCB有前途,但药物排泄支架 (DES) 仍然是某些复杂的病变类型的首选选择.
目前正在进行的临床试验预计将提供更多关于DCB在各种干预心脏病情景中的有效性和安全性的确切数据.

关键词:

冠状动脉疾病是一种冠状动脉疾病."新冠冠状动脉病" (de novo) 是一种冠状动脉疾病.用药物涂层的气球.药物释放的支架可以释放药物.在静脉支架内恢复缩.通过皮肤进行冠状动脉干预.小血管疾病 - 小血管疾病支架凝血症支架凝血症

更多相关视频

The Intra-Aortic Balloon Pump

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 12, 2018

相关概念视频

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...